Literature DB >> 20017727

Endogenous cannabinoid and opioid systems and their role in nicotine addiction.

Rafael Maldonado1, Fernando Berrendero.   

Abstract

Nicotine addiction is a complex behavioural alteration, in which many neuronal pathways and neurotransmitters are involved. For a long time, dopamine has been considered one of the most important neurotransmitters in mediating the rewarding effects of nicotine. In addition, a great amount of research suggests that the endogenous cannabinoid and opioid systems play an overall modulatory effect on the reward circuitry and participate in the addictive properties of most of the prototypical drugs of abuse. This review focuses on recent behavioural and biochemical data involving these systems in the different processes that contribute to tobacco addiction. A possible role for the endogenous cannabinoid and opioid systems in the rewarding properties of nicotine as well as in the development of nicotine physical dependence and relapse to nicotine-seeking behaviour will be examined. According to preclinical studies, clinical trials suggest that the manipulation of these systems with cannabinoid or opioid antagonists could be a potential therapeutical strategy for treating nicotine addiction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20017727     DOI: 10.2174/138945010790980358

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  11 in total

Review 1.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

2.  Cannabinoid receptor CB1 is involved in nicotine-induced protection against Aβ1-42 neurotoxicity in HT22 cells.

Authors:  Mingchun Wu; Ji Jia; Chong Lei; Ling Ji; Xiaodan Chen; Hanfei Sang; Lize Xiong
Journal:  J Mol Neurosci       Date:  2014-09-28       Impact factor: 3.444

3.  Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence.

Authors:  Shanna Babalonis; Sharon L Walsh
Journal:  Eur Neuropsychopharmacol       Date:  2020-04-06       Impact factor: 4.600

4.  THC exposure during adolescence does not modify nicotine reinforcing effects and relapse in adult male mice.

Authors:  África Flores; Rafael Maldonado; Fernando Berrendero
Journal:  Psychopharmacology (Berl)       Date:  2019-12-19       Impact factor: 4.530

Review 5.  Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.

Authors:  Maria Scherma; Anna Lisa Muntoni; Miriam Melis; Liana Fattore; Paola Fadda; Walter Fratta; Marco Pistis
Journal:  Psychopharmacology (Berl)       Date:  2016-01-04       Impact factor: 4.530

Review 6.  Mechanistic insights into nicotine withdrawal.

Authors:  Michael Paolini; Mariella De Biasi
Journal:  Biochem Pharmacol       Date:  2011-07-20       Impact factor: 5.858

Review 7.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase.

Authors:  Alessio De Simone; Gian Filippo Ruda; Clara Albani; Glauco Tarozzo; Tiziano Bandiera; Daniele Piomelli; Andrea Cavalli; Giovanni Bottegoni
Journal:  Chem Commun (Camb)       Date:  2014-05-18       Impact factor: 6.222

9.  Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition.

Authors:  Andrea Cippitelli; Giuseppe Astarita; Andrea Duranti; Giovanni Caprioli; Massimo Ubaldi; Serena Stopponi; Marsida Kallupi; Gianni Sagratini; Fernando Rodrìguez de Fonseca; Daniele Piomelli; Roberto Ciccocioppo
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

10.  Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results.

Authors:  Cristina Fernández-Fernández; Luis F Callado; Rocío Girón; Eva Sánchez; Amaia M Erdozain; José Antonio López-Moreno; Paula Morales; Fernando Rodríguez de Fonseca; Javier Fernández-Ruiz; Pilar Goya; J Javier Meana; M Isabel Martín; Nadine Jagerovic
Journal:  Drug Des Devel Ther       Date:  2014-02-20       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.